Payment overview · 2025
General Payments
$221.52
13 reported records · 11 companies
Healthcare provider profile · identity verified
William D Wagner, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WALLA WALLA, WA · NPI 1871567941
Verified facts
What the public records show
CMS Open Payments records show William D Wagner, D.O. received $221.52 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.70 | 15.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.12 | 14.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.34 | 10.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.17 | 10.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.21 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.99 | 8.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.92 | 7.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.24 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.15 | 6.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.06 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.62 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.52 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 445 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 94 |
| Omeprazole | Omeprazole | 366 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 77 |
| Gabapentin | Gabapentin | 360 | 61 |
| Metformin Hcl | Metformin Hcl | 352 | 74 |
| Losartan Potassium | Losartan Potassium | 251 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 208 | 66 |
| Meloxicam | Meloxicam | 202 | 61 |
| Glimepiride | Glimepiride | 184 | 39 |
| Trazodone Hcl | Trazodone Hcl | 184 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 52 |
| Potassium Chloride | Potassium Chloride | 157 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 145 | 22 |
| Atenolol | Atenolol | 144 | 30 |
| Tramadol Hcl | Tramadol Hcl | 142 | 31 |
| Furosemide | Furosemide | 129 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 23 |
| Simvastatin | Simvastatin | 110 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 22 |
| Sertraline Hcl | Sertraline Hcl | 104 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 30 |
| Clonazepam | Clonazepam | 99 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 14 |
| Donepezil Hcl | Donepezil Hcl | 89 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 20 |
| Finasteride | Finasteride | 87 | 20 |
| Famotidine | Famotidine | 86 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 12 |
| Eliquis | Apixaban | 75 | suppressed |
| Lorazepam | Lorazepam | 73 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 14 |
| Metformin Hcl Er | Metformin Hcl | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 14 |
| Allopurinol | Allopurinol | 66 | 11 |
| Lovastatin | Lovastatin | 65 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Prednisone | Prednisone | 39 | 16 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Sucralfate | Sucralfate | 32 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nystatin | Nystatin | 26 | 15 |
| Ramipril | Ramipril | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 14 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.52 · 13 records | PFIZER INC. | AJOVY, CREON, INJECTAFER, Kerendia, Korlym, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error